Saudi Arabia · Delayed Price · Currency is SAR Specialized Medical Company Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw resilient financial and operational results, with revenue and profit growth driven by improved utilization and expansion of acute and outpatient services. Despite seasonality and regional disruptions, guidance and major expansion projects remain on track.
Fiscal Year 2025
-
Strong revenue and profit growth in 2025 driven by acute and outpatient expansion, with a 43.7% rise in net profit and improved margins. Guidance for 2026 is conservative due to ramp-up delays and market competition, but expansion and capital discipline continue.
-
Q3 2025 saw strong revenue and profit growth, driven by a strategic shift to acute and outpatient services, with EBITDA margin rising to 27.3%. Expansion continues with new clinics and hospitals, a SAR 200 million special dividend, and robust guidance for year-end.